Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors.

Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Al Baghdadi T, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.3356.2019. doi: 10.1158/1078-0432.CCR-19-3356. [Epub ahead of print]

PMID:
31969335
2.

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).

Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K.

Clin Cancer Res. 2019 Dec 15;25(24):7497-7505. doi: 10.1158/1078-0432.CCR-19-0877. Epub 2019 Sep 23.

PMID:
31548349
3.

The Gift of Dying With Control.

Blanke CD.

Pract Radiat Oncol. 2019 Nov;9(6):387-388. doi: 10.1016/j.prro.2019.09.002. Epub 2019 Sep 13. No abstract available.

PMID:
31525423
4.

Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.

Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc M, Blanke CD.

JAMA Netw Open. 2019 Sep 4;2(9):e1910593. doi: 10.1001/jamanetworkopen.2019.10593.

5.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.

J Clin Oncol. 2019 Oct 10;37(29):2620-2631. doi: 10.1200/JCO.19.01019. Epub 2019 Aug 13.

6.

Trends in Medical Aid in Dying in Oregon and Washington.

Al Rabadi L, LeBlanc M, Bucy T, Ellis LM, Hershman DL, Meyskens FL Jr, Taylor L, Blanke CD.

JAMA Netw Open. 2019 Aug 2;2(8):e198648. doi: 10.1001/jamanetworkopen.2019.8648.

7.

Reply to S. Sorscher.

Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O.

J Clin Oncol. 2019 Sep 1;37(25):2291-2293. doi: 10.1200/JCO.19.01366. Epub 2019 Jul 3. No abstract available.

PMID:
31268798
8.

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O.

J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1. Erratum in: J Clin Oncol. 2020 Feb 20;38(6):656.

9.

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.

Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O.

J Clin Oncol. 2019 May 10;37(14):1217-1227. doi: 10.1200/JCO.18.01798. Epub 2019 Mar 13.

PMID:
30865548
10.

Let's Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine.

Tenner L, Hlubocky FJ, Blanke CD, LeBlanc TW, Marron JM, McGinnis MM, Spence RA, Taylor LP.

J Oncol Pract. 2019 Jan;15(1):44-49. doi: 10.1200/JOP.18.00432. Erratum in: J Oncol Pract. 2019 Mar;15(3):162.

11.

Current Activities of the Coalition of Cancer Cooperative Groups.

Bertagnolli MM, Blaney SM, Blanke CD, Curran WJ, Dancey J, Mannel RS, O'Dwyer PJ, Schnall MD, Wolmark N; Coalition of Cancer Cooperative Groups.

J Natl Cancer Inst. 2019 Jan 1;111(1):11-18. doi: 10.1093/jnci/djy190.

12.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL.

Cancer Epidemiol. 2018 Aug;55:117-122. doi: 10.1016/j.canep.2018.06.005. Epub 2018 Jun 21.

13.

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.

Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD.

Am J Clin Oncol. 2018 Dec;41(12):1193-1198. doi: 10.1097/COC.0000000000000465.

14.

A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.

Deverka PA, Bangs R, Kreizenbeck K, Delaney DM, Hershman DL, Blanke CD, Ramsey SD.

J Natl Cancer Inst. 2018 Jun 1;110(6):553-559. doi: 10.1093/jnci/djy064. Review.

15.

Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.

Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS.

Clin Colorectal Cancer. 2018 Mar;17(1):e121-e125. doi: 10.1016/j.clcc.2017.10.008. Epub 2017 Oct 24.

16.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.

Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.

17.

Responding to Patient Requests for Hastened Death: Physician Aid in Dying and the Clinical Oncologist.

Spence RA, Blanke CD, Keating TJ, Taylor LP.

J Oncol Pract. 2017 Oct;13(10):693-699. doi: 10.1200/JOP.2016.019299. Epub 2017 Sep 15.

18.

The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.

Unger JM, LeBlanc M, Blanke CD.

JAMA Oncol. 2017 Oct 1;3(10):1345-1351. doi: 10.1001/jamaoncol.2017.0762.

19.

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS.

J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6.

20.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

21.

Words matter: Restoring respect and dignity when referring to individuals with cancer.

Ellis LM, Blanke CD, Kohn EC.

Cancer. 2017 Jul 1;123(13):2390-2391. doi: 10.1002/cncr.30625. Epub 2017 Feb 9. No abstract available.

22.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS.

JAMA Oncol. 2017 Apr 1;3(4):516-522. doi: 10.1001/jamaoncol.2016.5383.

23.

American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.

Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CD.

J Clin Oncol. 2016 May 20;34(15):1803-12. doi: 10.1200/JCO.2016.67.2014. Epub 2016 Apr 11.

PMID:
27069078
24.

Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?

Blanke CD, DeMatteo RP.

JAMA Oncol. 2016 Jun 1;2(6):721-2. doi: 10.1001/jamaoncol.2016.0094. No abstract available.

PMID:
27031092
25.

The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.

Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL.

JAMA Oncol. 2016 Jul 1;2(7):875-81. doi: 10.1001/jamaoncol.2015.6487.

26.

Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future.

Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, Bleyer WA, Freyer DR, Geiger AM, Hayes-Lattin B, Tricoli JV, Wagner LI, Zebrack BJ.

Cancer. 2016 Apr 1;122(7):988-99. doi: 10.1002/cncr.29870. Epub 2016 Feb 5. Review.

27.

S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.

Blanke CD, Rankin C, Corless C, Eary JF, Mulder K, Okuno SH, George S, Heinrich M.

Oncologist. 2015 Dec;20(12):1353-4. doi: 10.1634/theoncologist.2015-0295. Epub 2015 Nov 17.

28.

The Globalization of Cooperative Groups.

Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD.

Semin Oncol. 2015 Oct;42(5):693-712. doi: 10.1053/j.seminoncol.2015.07.003. Epub 2015 Jul 10. Review.

29.

Progress and Infrastructure for Improved Patient Outcomes of the National Cancer Institute Network Groups.

Blanke CD, Curran WJ Jr.

Semin Oncol. 2015 Oct;42(5):679-80. doi: 10.1053/j.seminoncol.2015.07.004. Epub 2015 Jul 10. No abstract available.

PMID:
26433548
30.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

31.

Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No Harm.

Blanke CD, Fromme EK.

JAMA Oncol. 2015 Sep;1(6):785-6. doi: 10.1001/jamaoncol.2015.2379. No abstract available.

PMID:
26203585
32.

Losing "Losing the Battle With Cancer".

Ellis LM, Blanke CD, Roach N.

JAMA Oncol. 2015 Apr;1(1):13-4. doi: 10.1001/jamaoncol.2014.188. No abstract available.

PMID:
26182295
33.

Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.

Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS Jr.

Liver Cancer. 2015 Mar;4(2):115-25. doi: 10.1159/000367734.

34.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD.

J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.

35.

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD.

Cancer. 2015 Jul 1;121(13):2193-7. doi: 10.1002/cncr.29363. Epub 2015 Mar 30.

36.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

37.

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.

Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg K, Makar KW, Zhang W, Benedetti JK, Lenz HJ.

Clin Cancer Res. 2015 Apr 1;21(7):1583-90. doi: 10.1158/1078-0432.CCR-14-0857. Epub 2015 Jan 14.

38.

Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial.

Christen WG, Glynn RJ, Gaziano JM, Darke AK, Crowley JJ, Goodman PJ, Lippman SM, Lad TE, Bearden JD, Goodman GE, Minasian LM, Thompson IM Jr, Blanke CD, Klein EA.

JAMA Ophthalmol. 2015 Jan;133(1):17-24. doi: 10.1001/jamaophthalmol.2014.3478.

39.

Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).

Ulrich CM, Rankin C, Toriola AT, Makar KW, Altug-Teber Ö, Benedetti JK, Holmes RS, Smalley SR, Blanke CD, Lenz HJ.

Cancer. 2014 Nov 1;120(21):3329-3337. doi: 10.1002/cncr.28830. Epub 2014 Jul 15.

40.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD.

Cancer. 2014 Oct 1;120(19):2980-5. doi: 10.1002/cncr.28744. Epub 2014 Jul 16.

41.

Effect of M1a and M1b category in metastatic colorectal cancer.

Kennecke H, Yu J, Gill S, Cheung WY, Blanke CD, Speers C, Woods R.

Oncologist. 2014 Jul;19(7):720-6. doi: 10.1634/theoncologist.2013-0442. Epub 2014 Jun 4.

42.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.

J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3462.

43.

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.

El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD.

Br J Cancer. 2014 Feb 18;110(4):882-7. doi: 10.1038/bjc.2013.801. Epub 2014 Jan 14.

44.

Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer.

Kennecke H, Chen L, Blanke CD, Cheung WY, Schaff K, Speers C.

Curr Oncol. 2013 Dec;20(6):326-32. doi: 10.3747/co.20.1600.

45.

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).

Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF, Gold PJ, Blanke CD.

Br J Cancer. 2013 Oct 1;109(7):1744-9. doi: 10.1038/bjc.2013.517. Epub 2013 Sep 10.

46.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group.

Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27.

47.

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF.

Ann Oncol. 2013 Jul;24(7):1754-61. doi: 10.1093/annonc/mdt106. Epub 2013 Mar 22.

48.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team.

J Am Coll Surg. 2012 Jul;215(1):53-9; discussion 59-60. doi: 10.1016/j.jamcollsurg.2012.05.008.

49.

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS.

J Clin Oncol. 2012 Jul 1;30(19):2327-33. doi: 10.1200/JCO.2011.36.7136. Epub 2012 May 14.

50.

Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

Tomblyn MB, Goldman BH, Thomas CR Jr, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD; SWOG GI Committee.

J Thorac Oncol. 2012 May;7(5):906-12. doi: 10.1097/JTO.0b013e31824c7bed.

Supplemental Content

Loading ...
Support Center